KMT2A and acute myeloid leukemia: In a study aimed at identifying effectors mediating DOT1L inhibitory therapy in MLL-r AML, a genome-wide shRNA screen (92,425 shRNAs targeting 16,924 mouse genes) was performed in mouse Dot1lf/f-MLL-AF9 leukemic cells [20].